I N T RO D U C T I O N
Chronic kidney disease (CKD) is an important public health problem and recent estimates based on the National Health and Nutrition Examination Survey indicate that in the USA ∼17 million adults have moderate-to-severe CKD [i.e. estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 ] [1] . A common complication in moderate-to-severe CKD is anemia [2] [3] [4] , largely due to declining endogenous erythropoietin production by the damaged kidneys [5] . Studies have shown that reduced kidney function is strongly associated with a higher prevalence of anemia [4, 6] .
Prior to the development of erythropoiesis-stimulating agents (ESAs), red blood cell (RBC) transfusions were commonly used to treat anemia in CKD [7] . ESAs have been shown to effectively treat anemia in CKD patients and decrease the risk of receiving RBC transfusions [8, 9] . This is viewed as an important benefit because chronic transfusions have well-established risks including transmission of blood-borne diseases; iron, volume and potassium overload [10] [11] [12] [13] ; and, particularly relevant to CKD patients, the development of antibodies to foreign antigens (allosensitization) [14] [15] [16] . The presence and degree of allosensitization can adversely impact on kidney transplant outcomes in multiple ways, including the availability of fewer suitable organs, resulting in increased wait time for a transplant and shortened graft survival [15, 17, 18] .
The rate of RBC transfusions among CKD patients not on dialysis (CKD-ND) who are ≥65 years is estimated at 11-14/ 100 person years (PYs) [7] and is nearly twice as high in patients with diagnosed anemia [7, 19] . In CKD-ND patients younger than 65 years, however, there are limited data on the rate of RBC transfusions. We used data from a US health plan to investigate the use of RBC transfusions among adults younger than 65 years of age with diagnosed CKD-ND between 2002 and 2008. We also sought to identify patient characteristics that may alter the risk of receiving a RBC transfusion.
M AT E R I A L S A N D M E T H O D S

Data source
This analysis utilizes data from the Ingenix (OptumInsight) medical claims database [20, 21] . There are ∼40 million patients on the database from 2002 to 2008. The Ingenix database contains pharmacy, procedure and medical claims data for patients enrolled in a large, geographically diverse US health plan. The health plan provides coverage for physician, hospital and prescription drug services, and captures medical claims and encounter data from all available healthcare sites (inpatient, outpatient, emergency room etc.). Each service record contains information on up to five diagnoses, recorded with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and up to four procedures recorded with ICD-9-CM procedure codes, Current Procedural Terminology codes or Health Care Financing Agency Common Procedure Coding System codes. Outpatient laboratory test results were linked to the medical and pharmacy claims data only if they were sent to one of two laboratories, LabCorp or Quest, which are owned and operated by the health plan; consequently, laboratory data were available for only ∼20% of patients. All data were de-identified to assure confidentiality and were compliant with the 1996 Health Insurance Portability and Accountability Act.
Study population
Patients with diagnosed CKD were identified using all inpatient and outpatient medical claims from 2002 to 2008 based on the presence of one inpatient or two outpatient claims (separated by ≥90 days) with a CKD diagnosis (for diagnosis codes , see Supplementary data, Table S1 ) [22] . Additionally, we required patients to be 18-64 years of age at diagnosis. We required all eligible patients to have continuous coverage for 12 months before the index date (hereinafter referred to as the 'baseline period'), where the index date was defined as the date of the first inpatient or the second outpatient CKD diagnosis. We grouped patients by calendar year of their CKD diagnosis. Patients were excluded if they had evidence of end-stage renal disease (ESRD) requiring renal replacement therapy, cancer, previous kidney transplantation, hemolytic anemia, aplastic anemia, sickle cell anemia, coagulation defects, myelofibrosis or myelodysplasia during the baseline period. ESRD during the baseline period was defined as 6+ records of renal replacement therapy within 14 consecutive days (Supplementary data, Table S1 ).
Outcome
The primary outcome of interest was an inpatient or outpatient RBC transfusion event (Supplementary data, Table S1 ) during the year following a patient's index CKD diagnosis. We considered multiple transfusion events occurring within a 1-week period as a single-transfusion event. We distinguished between transfusion events occurring concomitantly to an acute bleeding event (i.e. as a result of trauma, gastrointestinal (GI) bleeding or surgery within 3 days prior to the transfusion) versus those not occurring concomitantly to such an event (Supplementary data, Table S2 ). Patients were followed from their index date to the first occurrence of death, termination of enrollment (>31-day gap in coverage), an incident diagnosis of an exclusionary condition (defined above) or 365 days following the index date.
Covariates
Patient characteristics were assessed during the baseline period and included demographics [age in years, gender, region (northeast, south, midwest or west)]; use of anemia therapy (ESA use, iron use, RBC transfusions); comorbid conditions based on one inpatient or two outpatient diagnoses [23] including: anemia, arteriosclerotic heart disease, acute myocardial infarction, congestive heart failure, cerebrovascular accident, transient ischemic attack, peripheral vascular disease, dysrhythmia, other cardiovascular disease, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, gastrointestinal disorders, liver disease and diabetes; concomitant medication use of anticoagulants/antiplatelets (aspirin, clopidogrel, ticlopidine, warfarin and heparin) and an indicator for any nephrologist care (Supplementary data, Table S1 ). Participants progressing to ESRD in the year following the index date
were identified using the same approach as previously discussed. We also used stage-specific CKD codes to characterize participants for the years 2006-08 (CKD stage-specific codes were introduced in 2006).
Serum creatinine and hemoglobin measurements were available for a subset of patients. We calculated the eGFR by year using the Chronic Kidney Disease Epidemiology Collaboration equation in all patients with available serum creatinine [24] . We assessed hemoglobin values in those receiving transfusions (using the mean of all hemoglobin measurements in the 3 months prior to the transfusion date) and those not receiving transfusions (using the mean of all hemoglobin measurements during the 1-year follow-up period).
Statistical analyses
We report characteristics of study participants overall and by year of CKD diagnosis. We compared hemoglobin concentrations in patients who did and did not receive a transfusion during the follow-up. We used a negative binomial regression model to estimate the 1-year RBC transfusion rate and corresponding 95% confidence intervals (CIs). These analyses were conducted for the population overall, by year and within patient subgroups.
We used Cox proportional hazards regression to identify patient characteristics associated with the time to first transfusion for the most contemporary cohort (2007-08). We limited our selection of possible predictors to a set of well-defined patient characteristics commonly assessed in studies of CKD-ND patients (see section 'Covariates'). We calculated the unadjusted transfusion hazard ratio for each candidate variable and only those with a P-value <0.20 were entered into the multivariate model. We then used a backward selection strategy to eliminate variables from the final model such that only those with a Pvalue <0.01 were retained. Because we were a priori interested in the effect of nephrologist care on transfusions, we included nephrologist care in our final model, irrespective of meeting the pre-specified cut-points for entry specified for other variables. We assessed the discriminative ability of the final model using Harrell's c-index [25, 26] . To evaluate external validity, we used the intercept and β coefficients from the final model using the 2007-08 data and assigned a predicted probability of transfusion to the 2006 CKD study population. Using these predicted values, we then calculated Harrel's c-index for the 2006 data. All analyses were conducted using SAS v9.2 (Cary, NC, USA).
R E S U LT S
Patient characteristics
There were 261 485 patients diagnosed with CKD between 2002 and 2008. Of these, 120 790 patients met the inclusion/ exclusion criteria ( Figure 1 ). The largest reduction in the sample occurred as a result of restricting the study population to patients aged 18-64 years. The majority of patients was 50-64 years of age, male and resided in the south ( Table 1) . The proportion of patients 50-64 years of age increased from 50 to 58% over the study period; otherwise, there were few changes in the demographic profile of patients over time. The proportion of patients receiving ESA therapy ranged from 8. 
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calendar year (Table 2 ). We present yearly transfusion rates for those patients not included in the study, according to their exclusion condition in Supplementary data, Table S3 . The transfusion rate was higher for older patients, females and those residing in the south rates were also higher with increasing severity of CKD. Table S4 ).
Characteristics associated with receiving an RBC transfusion (2007-08) All CKD-ND patients (n = 43 390), all transfusions (n = 770). Most baseline characteristics, including ESA use, RBC transfusions, peripheral vascular disease, GI disorders and diagnosed anemia, were independently associated with receiving a transfusion (Table 3) 
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Hemoglobin data (2002-08).
For patients with no transfusions during the 1-year follow-up period but who had available hemoglobin data (n = 21 848), the mean (SD) hemoglobin (g/dL) was 12.8 (1.8). In contrast, for patients with ≥1 transfusion during the follow-up who had hemoglobin data (n = 364), the mean (SD) hemoglobin (g/dL) during the 3 months prior to the transfusion was 10.4 (1.8).
D I S C U S S I O N
In this study of ∼121 000 individuals 18-64 years of age with CKD-ND, the transfusion rate was 2.64/100 PYs and remained relatively constant over the 7-year study period. Rates were lower if transfusions occurring concomitantly to an acute bleeding event were excluded. Transfusion rates were substantively higher among specific subgroups, particularly those who previously received transfusions, those diagnosed with anemia and those who progressed to ESRD. The transfusion rate increased with higher CKD stage and was the highest among CKD Stage 5 patients, those most likely to progress to ESRD. Among patients who progressed to ESRD in each year, the transfusion rate more than doubled over the study period and was 49.7/100 PYs in 2008. In multivariate adjusted models, patient factors most strongly associated with receiving a transfusion included previous transfusion and a diagnosis of anemia; patients receiving nephrologist care were less likely to receive a transfusion. Transfusions present potentially significant clinical consequences in patients with CKD, including the development of allosensitization [14] [15] [16] , and this effect has been confirmed recently in studies using single-bead antigen-antibody testing [27, 28] . Studies have shown that the development of allosensitization can delay or even prohibit eligibility for kidney transplantation and can significantly reduce graft survival [17, 18, 29] . For patients who progress to ESRD, for whom renal transplantation is the only alternative to chronic dialysis therapy, transfusion-related allosensitization remains a central concern [30, 31] . In this study, the transfusion rate among patients progressing to ESRD was substantially elevated and more than doubled over the study period, suggesting an opportunity for more focused intervention to prevent transfusions.
In the dialysis population, the transfusion rate declined with the introduction and routine use of ESA therapy [22, 32] . This same benefit has been demonstrated in the CKD-ND population [8, 9] . However, ESAs are used far less frequently in anemic CKD-ND patients [33, 34] and recent observational studies in the Medicare and VA populations have reported annual transfusion rates in this population ranging from 11 to 35% [7, 21] . Younger CKD-ND patients have not been studied previously and our findings suggest that transfusions in this population, particularly among those with more advanced disease, are comparable with estimates in older CKD-ND patients. This study suggests that younger CKD-ND patients with more advanced disease (Stage 4 or 5) may be those for whom the transfusion risk is greatest. Additionally, although laboratory data were available for only ∼20% of patients, those who received a transfusion had a mean hemoglobin concentration of 10.4 g/dL within the previous 3 months, which is consistent with data suggesting that patients with hemoglobin <10 g/dL are at a higher risk of transfusion [19, 35] .
Unlike the ESRD population, where the dialysis facility is responsible for managing anemia, patients with CKD-ND receive medical care from multiple physicians and specialists who may be unaware of their underlying CKD [36] and the specific risks that RBC transfusions pose to those patients. In the current study, there is some evidence that seeing a nephrologist was associated with a lower risk of receiving an RBC transfusion. This may be due to better appreciation of the importance of transfusion avoidance by nephrologists [29] and suggest that some of these transfusions can be avoided.
In this study, we sought to estimate the burden of transfusions and limited our investigation to those transfusions that might be avoided through the use of alternative therapies (e.g. ESAs and iron). To that end, we excluded patients with conditions that might not be appropriate for such therapies. We 
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also attempted to differentiate between transfusions that did and did not occur concomitantly to an acute bleeding event by identifying transfusions occurring ≤3 days following potentially significant bleeding events. Nonetheless, in multivariate analyses, we observed that many factors associated with receiving a transfusion were the same irrespective of whether the transfusion occurred in close proximity to a bleeding event. This suggests that CKD-ND patients have less reserve (especially those with advancing CKD and anemia) and are at a higher risk of being transfused in all settings. If CKD-ND patients with the highest transfusion risk can be readily identified (e.g. those likely to progress to ESRD), the transfusion risk in all settings, emergent and non-emergent, may be mitigated. This study should be evaluated in light of the following limitations. First, the increase in CKD-ND patients over time should be interpreted as being largely due to an increase in number of patients in the database. Secondly, hemoglobin and serum creatinine data were not available for the vast majority (>80%) of patients included in our study. Although laboratory results are likely missing at random, they are only available for a small proportion of patients, they are only captured in the outpatient setting, and they are rarely captured proximate to a transfusion event, and therefore we did not include hemoglobin or serum creatinine (vis-a-vis eGFR) in the multivariate analyses. Thirdly, we observed that patients who received an ESA during the baseline period ( presumably to treat their underlying anemia) had a higher incidence of transfusions during the follow-up period. The reduction in transfusions that occurs with ESA treatment is observed with chronic therapy [34] , but the current analysis examining 'use' in the baseline period does not distinguish between chronic and episodic therapy. Finally, we attempted to exclude from our analyses unavoidable transfusion events; however, given that the source data are administrative billing data, we were unable to determine the appropriateness of any of the transfusions administered during the study. Thus, the possibility that the use of transfusions was overestimated cannot be excluded.
In conclusion, in the current study, RBC transfusions occurred at a rate of 2.64/100 PYs in younger patients with CKD, with much higher rates seen among those with more advanced CKD and who are anemic. Also, for CKD-ND patients who progress to ESRD, the transfusion rate increased substantially between 2002 and 2008. Although not all transfusions can be avoided, a sizeable proportion may be preventable and awareness that patients with a history of transfusion, hemoglobin concentrations ∼10 g/dL and/or with advanced disease are at higher transfusion risk may help to prompt therapeutic interventions in place of transfusion. Since younger CKD-ND patients are those most likely eligible for kidney transplantation should they progress to ESRD, efforts to minimize transfusion are warranted.
C L I N I CA L S I G N I F I CA N C E
(1) RBC transfusions are relatively uncommon among younger patients with CKD-ND, except for those with anemia and more advanced disease. Among this population, the incidence of transfusion is comparable with that seen in older CKD patients and those receiving chronic dialysis.
(2) CKD-ND patients with the highest independent risk of receiving a RBC transfusion are those who have received previous transfusions, have documented anemia or hemoglobin concentrations approaching 10 g/dL and those not receiving nephrologist care.
(3) Individuals with CKD who ultimately progress to ESRD are those most likely eligible for a kidney transplant, and thus, those most directly affected by the sensitizing effects of blood.
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